Earliest stages of pulmonary fibrosis (subclinical ILD, interstitial lung abnormalities)[1]

Claire McGroder
Columbia University Irving Medical Center
2018 to 2022 · Last known relationship

Columbia University Irving Medical Center
2018 to 2022 · Last known relationship
Claire McGroder is an Assistant Professor of Medicine in Columbia's Division of Pulmonary, Allergy and Critical Care who cares for patients with interstitial lung disease and pulmonary fibrosis and runs ILD clinical trials. A Pomona College and UT Health San Antonio graduate, she completed internal medicine residency and the PCCM fellowship at Columbia (fellow 2018–2022, with a research project on risk factors for subclinical and clinical fibrotic lung disease), supported by a Columbia T32 in lung science (2020–2022) and a Mailman patient-oriented research grant (2021–2023). Her first-author work includes the Thorax study linking post-COVID pulmonary fibrosis to illness severity and leukocyte telomere length, MESA Lung analyses of interstitial lung abnormality incidence and biomarkers, and longitudinal follow-up of severe COVID-19 survivors; she is a frequent coauthor with Christine Kim Garcia, David Zhang and Matthew Baldwin. She also appears as a middle author on the highly cited Nature Medicine review of post-acute COVID-19 syndrome.
Each topic is linked to its supporting source in Sources.
Training includes Columbia University Irving Medical Center, MD, Pomona College, and University of Texas Health Science Center, San Antonio, plus 1 more record.
Explore education and trainingEarliest stages of pulmonary fibrosis (subclinical ILD, interstitial lung abnormalities)[1]
Interstitial lung disease and pulmonary fibrosis; ILD clinical trials[1]
Long-term pulmonary effects of COVID-19[1]